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Abstract 
Therapeutic angiogenesis is an attractive strategy to treat patients suffering from 
ischemic conditions and Vascular Endothelial Growth Factor-A (VEGF) is the master 
regulator of blood vessel growth. However, VEGF can induce either normal or aberrant 
angiogenesis depending on its dose localized in the microenvironment around each 
producing cell in vivo and on the balanced stimulation of Platelet-Derived Growth Factor-BB 
(PDGF-BB) signaling, responsible for pericyte recruitment. At the doses required to induce 
therapeutic benefit, VEGF causes new vascular growth essentially without sprouting, but 
rather through the alternative process of intussusception, or vascular splitting. Here we 
briefly review the therapeutic implications of controlling VEGF dose on one hand and 
pericyte recruitment on the other, as well as the key features of intussusceptive 
angiogenesis and its regulation. 
 
Introduction 
Atherosclerotic cardiovascular diseases, such as peripheral artery disease (PAD) and 
coronary artery disease (PAD), are the leading cause of death in the Western world [1]. 
Despite the possibility of pharmacological or surgical therapy, many patients with advanced 
ischemia are not satisfactorily treated by current procedures and require amputations or 
progress to heart failure [1, 2]. Therapeutic angiogenesis aims at restoring blood supply 
through the delivery of growth factors that stimulate the growth of new blood vessels, or their 
encoding genes, and is an actively investigated strategy to fill this unmet clinical need. 
Vascular Endothelial Growth Factor-A (VEGF) is the master regulator of vascular growth 
both in health and disease [3, 4] and is the main molecular target of therapeutic 
angiogenesis approaches. However, VEGF gene delivery failed to show clear clinical 
efficacy in several trials [5, 6]. Further, investigation in preclinical models uncovered key 
issues in VEGF biology that make it challenging to control its therapeutic potential with gene 
delivery. In fact, uncontrolled VEGF expression produces toxic effects, such as: a) the 
formation of vascular tumors (hemangiomas) in skeletal muscle, myocardium and other 
tissues after VEGF gene delivery by genetically modified progenitors [7, 8], plasmid [9] and 
viral vectors [10]; and b) vascular leakage and tissue edema, leading even to limb loss in 
preclinical ischemic models [11, 12]. Furthermore, VEGF can interfere with pericyte 
recruitment [13] and delay maturation of newly formed vessels, which are unstable and 
regress if the VEGF stimulus is withdrawn before about 4 weeks [14-16]. 
In order to exploit the therapeutic potential of VEGF, it is crucial to elucidate the cellular 
and molecular mechanisms of vascular growth induced by its over-expression at therapeutic 
doses. In fact, the best understood mechanism for vessel growth is sprouting, whereby a tip 
endothelial cell is generated and migrates towards a VEGF gradient, while neighboring 
endothelial cells acquire a stalk phenotype and proliferate without migrating to form the new 
vessel trunk [17]. However, we have recently found that VEGF overexpression at therapeutic 
doses induces vascular growth in skeletal muscle rather through the alternative mechanism 
of intussusception, i.e. circumferential enlargement of pre-existing vessels followed by 
longitudinal splitting [18]. Here we will briefly review the therapeutic implications of 
controlling VEGF dose on one hand and pericyte recruitment on the other, as well as the key 
features of intussusceptive angiogenesis and its regulation. 
 
VEGF dose: therapeutic implications  
Early attempts at determining the dose-dependent effects of VEGF gene delivery 
indicated an apparently very narrow therapeutic window in vivo, with increasing vector doses 
switching rapidly from being inefficient to causing angioma growth [9]. Subsequent studies 
revealed that spatial distribution of VEGF in the tissue plays a fundamental role in 
determining its therapeutic window, with significant implications for the design of delivery 
strategies. In fact VEGF binds to the extracellular matrix (ECM) with different affinity 
depending on the isoforms, with VEGF120 being the most soluble, VEGF188 the most binding 
and VEGF164 intermediate [19]. Elegant studies with transgenic mice, selectively expressing 
physiological levels of only one of the isoforms, showed that vascular networks induced by 
 3
VEGF120 or VEGF188 were both abnormal, with opposite phenotypes of dilated diameters and 
lack of branching, or very small and hyper-branched vessels, respectively [20]. However, 
physiological networks were induced by the intermediate VEGF164 isoform alone or, 
intriguingly, by VEGF120 and VEGF188 together [20], showing the importance of balanced 
gradients of factor to guide angiogenesis. 
We investigated the therapeutic implications of VEGF dose distribution in skeletal 
muscles by taking advantage of a highly controlled myoblast-based gene delivery platform 
that we developed over the past decade. In fact, the random integration of retroviral vectors 
within the genome of transduced myoblasts leads to different expression levels in individual 
cells. However, monoclonal populations, obtained by isolating single myoblasts from the 
heterogeneous transduced population, stably and homogeneously produced different 
amounts of VEGF164 from ~5 to ~200 ng/10
6 cells/day. While different amounts of the 
heterogeneous VEGF-expressing population always resulted in angioma growth, even with a 
total dose as low as 5 ng/106 cells/day, homogeneous expression of specific VEGF levels up 
to ~60 ng/106 cells/day by different clones induced only normal, stable and pericyte-coated 
capillaries, and angiomas appeared only above a threshold level of ~100 ng/106 cells/day 
[15]. Therefore, VEGF can induce normal or aberrant angiogenesis depending on its amount 
in the microenvironment around each producing cell in vivo and not simply on the total dose 
delivered, as different levels remain localized and do not average with each other in tissue. 
The control over dose distribution has remarkable functional consequences. In fact, 
delivery of the same total dose in a murine model of hindlimb ischemia (~60 ng/106 
cells/day) did not increase flow when this was the average of heterogeneous levels, but fully 
restored perfusion to non-ischemic levels when it was uniformly distributed in tissue by 
implanting a monoclonal population [21]. Interestingly, all doses inducing normal 
angiogenesis caused a similar 2-fold increase in the amount of newly induced vessels, 
whereas their diameter increased gradually with VEGF levels, always within the range of 
normal capillaries. This dose-dependent diameter increase was crucial for therapeutic 
improvement, as functional flow was not increased by lower VEGF levels (~5 ng/106 
cells/day) that induced the same amount of angiogenesis, but of significantly smaller size 
[21]. A dose-escalation study of adenoviral VEGF delivery to rabbit skeletal muscle also 
found that low vector doses caused sprouting of small-size capillaries and higher titers 
caused vessel enlargement, but functional benefits were achieved only with vascular 
enlargement [22]. 
These findings show that control over the microenvironmental distribution of VEGF levels, 
which is inherently challenging with gene therapy approaches, is critical to realize the 
therapeutic potential of VEGF. Towards this end, we recently developed a clinically 
applicable platform to achieve precise control over the dose, distribution and duration of 
recombinant VEGF delivery in vivo, based on the covalent cross-linking of an engineered 
VEGF protein into a fibrin hydrogel, similarly to the process of clot formation, and its 
subsequent release by controlled fibrinolysis in the tissue [23]. 
 
Pericytes and vascular maturation 
After endothelial activation by VEGF, the second and final stage of physiological 
angiogenesis is vascular maturation, whereby nascent structures are invested by pericytes, 
become quiescent and persist indefinitely [24]. Pericytes establish complex regulatory 
functions and have been shown to promote both vascular stabilization [25], i.e. the 
persistence of new vessels independently of continuous VEGF stimulation, and vascular 
normalization, i.e. the prevention of aberrant angiogenesis by excessive VEGF. Here we will 
focus on the therapeutic implications of pericyte recruitment in the context of normalization 
and modulation of VEGF dose-dependent effects. 
Pericytes, which express PDGF-Receptor- (PDGFR-), are recruited by Platelet-Derived 
Growth Factor-BB (PDGF-BB) produced by the activated tip cells of sprouting capillaries 
[26]. Mice lacking either the Pdgfb or Pdgfr-beta genes showed severely impaired pericyte 
recruitment and vascular abnormalities, with continued endothelial proliferation, 
microaneurysm formation and bleeding [26], similarly to the effects of deleting the Pdgfb 
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gene specifically in endothelial cells [27]. Pericytes regulate endothelial morphology and 
function both through cell-to-cell contact and paracrine signals that involve several 
pathways, such as Transforming-Growth Factor-β (TGF-β) and its receptors, angiopoietins-1 
and -2 (Ang-1 and Ang-2) and their receptor Tie2, and the Eph/Ephrin pathway [25, 28]. 
Targeting of these pathways is a promising approach to modulate the effects of VEGF 
delivery and to overcome its limitations. Ang-1 has been shown to protect adult vasculature 
from leakage and to counteract vascular permeability induced by VEGF and inflammation 
[29], while co-delivery of the Ang-1 gene could reduce VEGF-induced leakage in a rat model 
of hindlimb ischemia [30] and to promote the maturation of new vessels, which persisted 
after 4 weeks, but regressed in the presence of VEGF alone [31]. 
In the context of VEGF over-expression, the dose-dependent transition between normal 
and aberrant angiogenesis correlates with a loss of normal pericytes [15] and promoting 
pericyte recruitment by co-delivery of PDGF-BB can modulate the dose-dependent effects of 
VEGF. In fact, we found that the transition between normal and aberrant angiogenesis is not 
a fixed property of VEGF dose, but rather depends on the balance between the relative 
stimulation of VEGF and PDGF-BB signaling and co-delivery of the two factors completely 
prevented the induction of angioma-like structures regardless of VEGF dose, yielding 
instead only morphologically normal, mature and functionally perfused capillary networks 
[32]. However, since both factors are retained in the matrix immediately around expressing 
cells [19, 33], complete normalization of VEGF-induced angiogenesis required the precise 
co-localization of VEGF and PDGF-BB gradients in the microenvironment at fixed relative 
levels, through balanced co-expression from a single bicistronic construct, whereas 
expression from independent cell sources or separate vectors only had partial effects [32]. 
Adenoviral co-delivery of VEGF and PDGF-BB from two independent vectors even impaired 
pericyte recruitment to nascent vasculature [34], whereas similar adenoviral delivery from a 
single bicistronic vector yielded homogeneous and mature capillary networks [32], further 
highlighting the importance of the mode of factor delivery for the therapeutic outcomes. 
These results suggest that balanced co-expression of VEGF and PDGF-BB may overcome 
the intrinsic limitations of direct gene therapy approaches with VEGF alone, allowing safe 
and therapeutic angiogenesis despite heterogeneous VEGF levels of expression in vivo. 
 
Intussusceptive angiogenesis 
While most of our current understanding of the molecular regulation of vascular growth 
stems from powerful genetic models of sprouting angiogenesis, it is being increasingly 
recognized that the alternative process of intussusception, or vascular splitting, plays a 
significant role in physiological, pathological and therapeutic settings. 
Intussusceptive angiogenesis was first described during rat lung development, which 
entails a massive 35-fold increase in capillary volume during the first 4 postnatal months 
[35]. Rather than sprouting tips, multiple tiny holes were observed within the rapidly 
expanding microvessels by vascular corrosion casting and transmission electron microscopy 
showed that the hole profiles corresponded to slender transcapillary (intraluminal) tissue 
pillars with diameters of 1-2.5 µm (Fig. 1) [36, 37]. This process of vascular expansion 
through insertion of tissue pillars into the vessel lumen was named intussusception after the 
Latin for “growth within itself”. Alternative nomenclature includes “non-sprouting 
angiogenesis”, “inverse sprouting”, “luminal division” and “splitting angiogenesis”, the latter 
reflecting the fact that intussusception creates new vascular segments by splitting a solitary 
microvessel longitudinally into new daughter vessels. 
 
Mechanism of pillar formation and outcomes 
Four consecutive steps of pillar formation have been described during intussusception: I) 
a contact zone between opposing capillary walls is formed (Fig. 2a-b); II) a perforation of the 
bilayer contact zone is created (Fig. 2c); III) an interstitial tissue pillar core is shaped that is 
invaded by pericytes and myofibroblasts with deposition of collagen fibrils (Fig. 2d). During 
this phase the pillars have diameters up to 2.5µm; IV) the pillars increase in girth and could 
subsequently reshape, fusing with the neighbor pillars and eventually splitting the primary 
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vessel into two new segments. The last phase does not entail any further change in the pillar 
structure. 
Intussusceptive angiogenesis was subsequently also demonstrated in many tissues and 
species during both normal and pathological angiogenesis and it appears to be a general 
phenomenon. For more details, see recent review articles [38, 39]. 
Intussusception is involved in growth, remodeling and maturation of the vascular plexus, 
processes that have different morphological and functional outcomes: 1) the repetitive and 
alternating occurrence of pillars within the capillary bed initially leads to its rapid expansion 
and an increase in its complexity (intussusceptive microvascular growth); 2) pillars could 
appear in rows and then elongate and merge to segregate vascular segments that become 
small arteries and draining veins within the vascular tree (intussusceptive arborization) [40]; 
3) pillar formation occurring within the branching points of small arteries and veins can lead 
to remodeling via optimization of the branching geometry, such that eccentric repetitive pillar 
formation and fusion results in the exclusion and pruning of vessel branches 
(intussusceptive pruning) [41]. 
 
Blood flow and intussusception  
Vascular adaptation to blood flow was postulated almost 150 years ago by Wilhelm Roux 
in his doctoral thesis [42]. Djonov et al. [41] described for the first time the regulation of 
intissusception by hemodynamic conditions in the chicken choriaoallantoic membrane 
(CAM). By clamping one of the major arterial side-branches upstream of the investigated 
area acutely increased blood velocity. The resulting 50–60% surge in flow rate caused many 
of the vascular bifurcations within the areas of altered hemodynamics to undergo 
intussusceptive remodeling within 15 to 45 min after clamping. The rapidity of the response 
indicates that the haemodynamic trigger does not require changes in gene expression. 
Based on in vivo calculations of haemodynamic parameters, 3D computational modeling 
revealed that transluminal pillars were located in regions of low shear stress <1 dyne cm−2 
and flow simulations indicated that the pillars were spatially constrained by neighbouring 
regions of higher shear stress [43]. It should be pointed out that pillar development is caused 
by increased flow, but occurs in areas characterized by low shear and turbulent flow 
conditions [41, 43, 44]. 
 
VEGF and intussusception  
Recent data suggest that, in addition to haemodynamic forces, intussusception is also 
regulated by growth factors, particularly by VEGF. However, due to a paucity of appropriate 
experimental models, only scarce data are available on the molecular control of 
intussusception. In the rapidly developing chick glomeruli and lung, high VEGF levels were 
associated with the sprouting phase, while VEGF was downregulated during the phase of 
intussusceptive vascular growth [45, 46]. However, the temporal course of intussusception in 
the chicken CAM corresponded to VEGF expression in the microvasculature and inhibition 
of VEGF signaling retarded, but did not abolish, intussusceptive capillary maturation, 
suggesting that VEGF may not be essential for intussusceptive angiogenesis, but can 
promote it [47]. 
Taking advantage of the highly controlled myoblast-based platform for gene delivery to 
muscle described above, we recently found that over-expression of VEGF, at the doses 
required to induce therapeutic benefit, causes new vascular growth essentially without 
sprouting, but rather through an initial circumferential enlargement of pre-existing vessels, 
followed by transluminal pillar formation and intussusceptive longitudinal splitting [18]. 
Interestingly, intussusception was the cellular mechanism underlying both normal and 
aberrant angiogenesis, induced by different VEGF doses. However, high VEGF levels 
caused a greater initial enlargement than lower ones and, while intussusception was initiated 
in both cases, pillar formation could not be completed in the presence of larger diameters, 
leading to a failure to split into normal capillaries and to the continued circumferential growth 
of affected vascular segments into angioma-like structures [18]. 
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Conclusions 
Angiogenesis is a complex and highly regulated process. The design of rational 
therapeutic approaches to promote angiogenesis requires a thorough understanding of the 
mechanisms underlying the induction of physiological or aberrant vascular structures under 
therapeutic conditions, in which intussusception increasingly appears to play a fundamental 
role. Therefore, it will be key to elucidate the molecular mechanisms controlling 
intussusception, which are still poorly understood, compared to sprouting. As pericyte 
recruitment is a promising target to modulate VEGF dose-dependent effects and increase 
both safety and efficacy of VEGF gene delivery, it remains to be determined whether 
pericytes can control intussusception and through which molecular pathways. 
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Figure Legends 
Figure 1. Morphology of transluminal pillars. (a) Corrosion cast of blood vessels in which 
newly formed transluminal pillars appear as small holes (stars). (b) 3D reconstruction of a 
chick CAM transluminal pillar (displayed as hole in a): an erythrocyte (red) is represented 
behind the pillar (green). Size bars = 5µm. (Reproduced from [48]) and [40]). 
 
Figure 2. Morphogenic events during intussusception. (a-d) 3D scheme of transluminal pillar 
formation, the hallmark of intussusceptive angiogenesis. (a’–d’) 2D representation of the 
events in a–d. Endothelial cells (EC) on the opposite sides of a capillary protrude into its 
lumen until they make contact with each other. Once established, this contact is maintained 
by the formation of inter-endothelial junctions and reorganized so that the endothelial bilayer 
is perforated centrally. Endothelial cells then retract and the newly formed pillar increases in 
girth after being invaded by fibroblasts (Fb) and pericytes (Pr), which lay down collagen 
fibrils (Co). BM = basement membrane. (Reproduced from [49] and [48]. 
 


